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Abstract
Background: Resurgence or outbreak of measles recently occurred in both developed and developing countries 
despite long-standing widespread use of measles vaccine. Measles incidence in China has increased since 2002, 
particularly in infants and in persons ≥ 15 years of age. It is speculated that infants may acquire fewer measles IgG from 
their mothers, resulting in the reduced duration of protection during their early months of life. This study aimed to 
clarify the reason of increased susceptibility to measles in young infants in China. Measles IgG in 24 measles infants ≤ 9 
months of age and their vaccinated mothers was quantitatively measured. The mean measles neutralizing titer in the 
vaccinated mothers and in 13 age-match women with the histories of clinical measles were compared.
Results: All the mothers were confirmed to be vaccinated successfully by the presence of measles IgG. Six vaccinated 
mothers were positive for measles IgM and had high concentrations of measles IgG and the neutralizing antibody, 
indicating underwent natural boosting. The mean measles neutralizing titer in 18 vaccinated mothers without natural 
boosting were significantly lower than that in 13 age-match women with the histories of clinical measles (1:37 vs 1:182, 
P < 0.05).
Conclusions: Our results suggest that infants born to mothers who acquired immunity to measles by vaccination may 
get a relatively small amount of measles antibody, resulting in loss of the immunity to measles before the vaccination 
age. Measures to improve the immunity in young infants not eligible for measles vaccination would be critical to 
interrupt the measles transmission in China.
Background
Measles vaccine was introduced in China in 1965. Since
early 1980s, China has implemented a routine two-dose
vaccine schedule in children, with the first vaccinated at 8
months of age and the second given at 7 years old (shift to
18-24 months of age since 2006). Reported measles cases
in China substantially reduced; the annual incidence per
100 000 population dropped from 200-1500 cases before
the vaccine era to 5.7 cases between 1996 and 2000 [1].
However, during recent years, the annually measles cases
significantly increased. The reported cases rose from
74813 in 2003 and 71013 in 2004 to 124,219 in 2005 and
100,267 in 2006, with the incidences of 9.56 and 7.67 per
100 000 population respectively [2]. Moreover, the age
distribution of measles has changed markedly. In 1990s,
1.74% of reported cases occurred among children < 8
months of age [3]; however, of cases reported during 2003
and 2004, 4.31% and 2.25% occurred among children < 8
months of age respectively, and during 2005 and 2006, the
proportion of cases occurring in children < 8 months old
increased to 7.62% and 10.98% respectively [2]. In a hos-
pital in Shanghai, nearly 60% of 503 hospitalized children
with measles in 2005 were younger than 9 months old [4].
These data demonstrate that young infants in China have
increased susceptibility to measles virus.
Although low measles vaccine coverage was putatively
considered to be the main cause of the increased measles
cases in China [4,5], a nationwide survey in 2004 showed
that the measles IgG seroprevalence was as high as 92.9%
in children aged 1 to 12 years [6], even slightly higher
than the prevalence of some 90% in 1990s [3], during
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Page 2 of 6which the measles incidence was lowest. Women who
recovered from measles usually have high measles anti-
body levels whereas those who did not have measles but
were successfully vaccinated have relatively lower anti-
body titers [7]. Currently, the measles antibodies in the
vast majority of mothers in China are induced by vaccina-
tion rather than by the natural infection. Therefore, it is
speculated that infants may acquire fewer antibodies
from their mothers, resulting in the reduced duration of
protection against measles and leading to the onset of
measles before the age of receiving vaccine. In this study,
we quantitatively measured the measles IgG in serum
samples collected from ill infants in the acute phase and
compared the neutralizing measles antibody in mothers
of the ill infants and in age-matched women who recov-
ered from measles. We found that mothers who were vac-
cinated with measles vaccine had significantly lower
measles antibody than the age-matched women who had
the histories of measles in their childhood. Our data sug-
gest that infants born to the vaccinated mothers may get a
relatively small amount of maternal measles antibody,
resulting in loss of the immunity to measles before the
vaccination age. Thus, measures to improve the immu-
nity in young infants not eligible for measles vaccination
would be critical to interrupt the measles transmission in
China.
Results and Discussion
Twenty-four ill infants aged ≤ 9 months old, hospitalized
from March 16 to July 16, 2007, and their 24 mothers
were enrolled in the study. Each clinically diagnosed case
was confirmed by positive measles IgM antibody. The
general characteristics of the ill infants and their mothers
are shown in Table 1. Five infants received the measles
vaccine 2-12 days before onset of the disease. The mean
time between blood sampling and onset of the fever was
6.2 days. All infants recovered and were discharged
within 3 weeks. All the mothers had the histories of mea-
sles vaccination but none of them had a history of clini-
cally and/or serologically confirmed measles, and had any
symptom when the blood samples were taken. The mean
age of the mothers was 28.3 years (24 to 32), comparable
to the mean age of 29.5 years (25 to 34) of 13 women who
had histories of clinically diagnosed measles.
All 24 mothers had detectable measles IgG antibody as
shown in Table 1. With the known vaccination histories
in these mothers, the results validate that all the mothers
had been successfully vaccinated. Surprisingly, some of
them had extremely high antibody titers. This had us sus-
pect whether these mothers were recently exposed to the
wild type virus because they took care of their ill infants,
resulting in anamnestic responses with a rapid rise of IgG
antibody known as natural boosting. Thus, we tested
measles IgM in all 24 mothers; 6 of them were positive
with the OD450 values ranging from 0.302-0.621 (Table
1). Infection of measles virus in persons with the history
of vaccination may have detectable IgM [8,9]. Compared
with the high concentrations of measles IgG in their sera
(Table 1), the relatively low OD450 values (0.302-0.621)
of the specific IgM in the ELISA test strongly suggest that
these 6 mothers were exposed to the virus in the presence
of pre-existing measles IgG, rather than the primary
infection in the absence of immunity, because the ratio of
IgM to IgG after re-exposure, if IgM is detected, is lower
than the ratio in previously unexposed persons [8]. These
data demonstrate that natural boosting occurred in these
mothers.
Meanwhile, we quantitatively measured the measles
IgG in ill infants' sera collected between 3-9 days after
onset of symptoms (Table 1), and compared the mean
titer in infants whose mothers were IgM negative with
that in infants whose mothers were IgM positive. Since
14% and 81% of the vaccinees will become positive for
measles IgG at week 2 and week 3 respectively after vacci-
nation [10], the measles IgG in the five vaccinated infants
might contain the antibody induced by the vaccine. Thus
we excluded these five infants in the comparison. The
mean measles IgG concentration in infants of the moth-
ers with negative measles IgM was 56 U/ml (43-82 U/ml),
whereas that in infants of the mothers with positive mea-
sles IgM was 65 U/ml (45-97 U/ml). The mean IgG values
in two groups of infants were comparable although the
antibodies in their mothers were 10 times different (5450
U/ml vs 57868 U/ml). Additionally, measles IgG in infants
No 3 and No 9 (Table 1), whose mothers were both posi-
tive for IgM, was far lower than the expected level based
on the decay rate with the IgG half-life of 23 days in
serum. Therefore, these data provide additional evidence
that the high measles IgG in the six mothers was the con-
sequence of recent subclinical infection, rather than the
pre-existing measles antibody.
Since the measles IgG detected by ELISA based on the
whole virus antigens is not all neutralizing, we analyzed
the measles neutralizing antibody by cell culture. Gener-
ally, as shown in Table 1, sera that contained high concen-
trations of measles IgG had high titers of neutralizing
activity. According to mothers' status of measles IgM, we
compared the measles neutralizing titers in the vacci-
nated mothers with those in 13 control women with the
histories of measles. As shown in Table 2, the mean titer
in the vaccinated mothers who had no serological evi-
dence of natural boosting was 37, while that in the 13
control women was 182; the difference was statistically
significant (P < 0.05). As expected, the mean neutralizing
titer in the six vaccinated mothers with recent natural
boosting reached to 1109, considerably higher (P < 0.05)
than either of the two other groups. In an early study
reported in 1961, Stokes et al [11] showed that after expo-
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sons with neutralizing titers from 2 to 8 experienced
subclinical reinfections, but none of the individuals with
titers from 16 to 128 was subclinically infected. In the
present study, of the 18 mothers without the serological
evidence of subclinical infections, 14 had neutralizing
titers from 16 to 192, two had the titer of 12, and only two
had the titers of 4 and 8. Therefore, it is highly possible
that neutralizing titers in the 6 mothers positive for mea-
sles IgM were < 8 when they labored their infants.
In this study, we expressed the measles IgG in U/ml
according to the reference provided by the ELISA kit
manufacturer, rather than in milli-international units per
milliliter based on the international standards. Thus, it is
difficult to compare our measles IgG levels with other
reports and with the conventionally accepted protective
level of 200 mIU/ml [12]. However, as reported by others
[13], we found that our ELISA measles IgG levels were
generally correlated with the neutralizing titers (Table 1).
Therefore, the measles IgG detected in this study
reflected the real situations and the antibody comparison
in the different groups was reliable.
In primary acute measles virus infection, detectable
specific IgG antibody generally appears in the serum dur-
ing late phase of the infection [14]. Thus, the measles IgG
in the ill infants within 3-9 days after onset should par-
tially contain, if not all, the maternally derived passive
antibody, indicating that maternal measles IgG in these
Table 1: Measles antibodies in sera from ill infants and their mothers
Pair No Mother Infantc
IgG (U/ml) NTa MV IgMb Age 
(month)




1 1272 12 - 3 M 5 49 -
2 42986 256 0.621 8 F 5 80 -
3 77355 >2048 0.302 5 M 7 97 -
4 1782 8 - 7 M 8 54 -
5 3735 32 - 8 M 8 82 -
6 75000 2048 0.552 8 M 7 39 -
7 7069 16 - 8 F 7 42 -
8 2577 32 - 7 M 6 53 -
9 75000 >2048 0.577 5 M 6 59 -
10 275 4 - 9 F 9 94 10
11 5261 24 - 7.5 M 4 73 -
12 55843 1024 0.489 9 M 8 110 6
13 5158 96 - 8 F 6 64 -
14 1391 16 - 8 M 6 52 -
15 23078 192 - 7 M 5 61 -
16 3398 24 - 8 M 3 72 8
17 4849 24 - 8 F 7 54 -
18 3205 16 - 8 F 6 428 12
19 2140 16 - 8.5 F 9 168 2
20 19002 >2048 0.376 6 M 5 50 -
21 2147 48 - 6 M 4 44 -
22 588 12 - 8 M 6 43 -
23 5433 32 - 9 M 5 45 -
24 11963 64 - 9 M 6 70 -
a NT, neutralizing titer.
b The assay's OD450 cut-off is 0.262; -, lower than 0.262.
c All infants were positive for measles IgM.
d -, not vaccinated; number indicates the days after measles vaccination.
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protection because of insufficient antibody acquired from
their mothers.
Epidemiologic studies demonstrate that the relative risk
of measles among infants whose mothers were born in
the vaccine era is greater than that among infants whose
mothers were born before availability of the measles vac-
cine [15]. In the present study, we found that all the 24
mothers had been vaccinated successfully; however, their
infants still developed measles before or around the age
of measles vaccination. Together with the low measles
IgG and neutralizing titers in the mothers when they
delivered their infants, our data strongly suggest that
infants born to mothers with the vaccine-acquired immu-
nity to measles will have short duration of protection
against measles.
Despite the widespread use of measles vaccine and suc-
cessful controls of the disease globally, resurgence of
measles occurred in both developed and developing
countries during past decade. In developed countries, rel-
atively low measles vaccination levels among preschool
children were attributed to the resurgence; the endemic
measles transmission has been interrupted by raising the
vaccination coverage in preschool children and perform-
ing the catch-up immunization in school children [16,17].
In developing world, however, in addition to suboptimal
vaccination coverage, other influential factors may be
involved in the resurgence since the high vaccination cov-
erage did not effectively hurdle endemic measles trans-
mission [18,19].
The results in the present study would be meaningful in
designing strategy in eliminating measles in developing
countries like China. In 2006, China set up the National
Plan for Elimination of Measles, aimed at reducing the
incidence below one case per one million population and
interrupting indigenous transmission of measles by 2012.
To achieve this goal, it is required to reach at least 95%
vaccine coverage through routine vaccination of infants
with the first dose given at 8 months of age and a second
dose at 18-24 months of age respectively and to intensify
catch-up vaccinations in older children at the entry of
kindergarten or elementary school as well as to take other
measures. However, the changing age distribution of
measles in infants younger than 1 year of age [2], which is
at least partially caused by low maternally acquired mea-
sles antibody as demonstrated in this study, casts doubt
on the effectiveness of current strategy in elimination of
measles. The current strategy can reduce the incidence in
general population and thereafter diminish exposure
opportunities of young infants to measles virus; however,
since infants younger than 8 months of age are not eligi-
ble for vaccination, many of them will remain to be sus-
ceptible to measles virus because of short duration of the
immunity conferred by maternal antibody. Susceptible
infants in countries with high measles incidences are at
considerable risks for the disease. Therefore, in addition
to the current strategy, innovative measures to improve
the immunity in young infants younger than 8 months of
age would be critical to achieve the goal of elimination of
measles in unindustrialized countries like China.
Conclusion
In conclusion, our results suggest that infants born to
mothers vaccinated with measles vaccine in their child-
hood will lose the immunity to measles earlier than those
born to mothers with the histories of measles. Although a
recent report shows that vaccination at an age of 4.5
months may curtail the measles in younger infants [19],
more reports demonstrate that vaccination in younger
infants (6-9 months of age) usually has lower seroconver-
sion rates and lower neutralizing titers compared with
immunization in old infants (12-15 months of age) [20]. It
appears to be logical and more practical to offer an addi-
tional measles vaccine in women before pregnancy so
that their future infants can get more maternal measles




Infants ≤ 9 months of age with the clinical diagnosis of
measles (fever, maculopapular rash with conjunctivitis,
Table 2: Measles IgG and neutralizing antibody in mothers and control women (range)
Subject Number Mean measles IgG in U/ml Mean reciprocal neutralizing 
titerd
Control womana 13 9653 (478-70506) 182 (16-1024)
Mother (-) for IgMb 18 4740 (275-23078) 37 (4-192)
Mother (+) for IgMc 6 57531 (19002-77355) 1109 (256-2048)
a With histories of measles in their childhood.
b Vaccinated without natural boosting.
c Vaccinated with recent natural boosting.
d P < 0.05, Kruskal-Wallis rank-sum test.
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Page 5 of 6rhinorrhea, or cough), hospitalized at the Nanjing Second
Hospital, Nanjing, China, between March 2007 and July
2007, were recruited. All mothers of the ill infants were
explained the study and invited to participate. Signed
informed consent was obtained from the mothers who
agreed and the infants' consent was signed by their moth-
ers. Blood samples were obtained from mothers and
infants by venepuncture within 24 hours after the admis-
sion. In addition, blood samples from 13 women who had
the histories of clinical measles were also included; the
samples were collected during summer and fall of 2007.
Sera were aliquoted and frozen at -20 °C. The study was
approved by the institutional review boards at the Nan-
jing Second Hospital and the Nanjing Drum Tower Hos-
pital.
Determination of measles IgM and IgG antibody
Measles IgM was tested by a measles virus IgM ELISA kit
(Euroimmun, Medizinische Labordiagnostika AG, Ger-
many). For quantitative determination of measles IgG,
serum samples were coded so that the laboratory was
unaware of which samples were from mothers and chil-
dren; however, the sera were arranged so that the samples
from an infant and his/her mother were analyzed in par-
allel. The measurements were performed with a measles
virus IgG ELISA kit (IBL, Hamburg, Germany) including
the standard measles virus IgG serials of 1, 10, 40, and
250 units per milliliter serum (U/ml). The ELISA is based
on the cell culture derived native virus antigens and the
cut-off is 10 U/ml. Each sample was diluted appropriately
so that the OD450 was located within the ranges of stan-
dard serials.
Measurement of measles neutralizing antibody
Measles neutralizing antibody in paired sera of the ill
infant and his/her mother was measured as described
elsewhere [21] with some modifications. Briefly, 25 μl of
serial two-fold dilutions (1:2 to 1:2048) of heat-inacti-
vated (56 °C for 30 min) serum prepared in DMEM
medium was preincubated with an equal volume of Mvi/
Jiangsu.PRC/28.05/1 strain of the measles virus contain-
ing 100 TCID50 at 37 °C for 3 hour, and then 50 μl of
Vero/SLAM cells (106 cells/ml) was added to the serum-
virus mixtures. Two wells were prepared for each dilution
and a control for cytotoxicity was included for each
serum. To assure constant amount of the live virus used
in experiments performed at different times, each test
also included virus back titration containing 1000, 100,
10, and 1 TCID50 virus. The cells were kept at 37 °C in 5%
CO2. On the next day, 100 μl of culture medium was
added to each well and the cells were cultured for 7 days.
Neutralization titers were expressed as the reciprocal of
the highest dilutions that did not induce cytopathic
effect. A serum with the neutralization titer of ≥ 1:2 was
considered to be positive.
Statistical Analysis
Analyses were performed with the SPSS Statistical Pack-
age version 12.0 (SPSS Inc, Chicago, IL). The Mann-
Whitney U and Kruskal-Wallis rank-sum tests were used
for comparisons of measles neutralizing antibody titers
between groups. A P value < 0.05 was considered statisti-
cally significant.
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